SummaryRMgm-206
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 16597467 Reference 2 (PMID number) : 18417228 Reference 3 (PMID number) : 25284813 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | K. Yano, S. Kawazu |
Name Group/Department | Research Institute |
Name Institute | International Medical Center of Japan |
City | Tokyo |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-206 |
Principal name | Prx-KO |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Reduced production of gametocytes (60% fewer gametocytes compared to wild type) |
Fertilization and ookinete | Not tested |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of oocyst are produced. The number of mature oocysts containing sporozoites and the number of salivary gland sporozoites is reduced compared to wild type. Infectivity of salivary gland sporozoites is reduced as shown by a prolonged pre-patent period after intravenous inoculation of sporozoites. |
Liver stage | Infectivity of salivary gland sporozoites is reduced as shown by a prolonged pre-patent period after intravenous inoculation of sporozoites. Slightly reduced liver stage development. |
Additional remarks phenotype | Mutant/mutation Protein (function) See also the paper: Turturice BA et al., 2013 PloS Pathogen 9(1): e1003136. In this paper they analysed 1-Cys Prx (PBANKA_122800) expression in the TPx-1 knock-out parasites. Additional information Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1302800 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1438900 | ||||||||||||||||||||||||
Gene product | thioredoxin peroxidase 1 | ||||||||||||||||||||||||
Gene product: Alternative name | TPx-1; Trx-Px1; TPx1: PfPRX-1 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | Both targeting regions contain part of the coding sequence | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |